Open an account

Axonics

AXNX · NASDAQ

$0.429−$0.0611 (−12.47%)TodayMarket closed ·
Prev close $0.4901

AXNX analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Nov 13, 2024

Bull case

Axonics Inc. demonstrates a significant improvement in its operating performance, with an operating margin of (0.7%), reflecting a substantial year-over-year increase of 2,260 basis points. The company also reported impressive sales growth for its key products, with Bulkamid sales rising 41.6% to $19.2 million and SNM sales increasing 30.1% to $73.9 million in Q3 2023, both surpassing market expectations. Additionally, Axonics raised its full-year revenue guidance by $4 million to a total of $362 million, indicating a robust projected growth of 32% year-over-year, alongside a strong gross margin of 74.2%, which further supports a positive financial outlook.

Bear case

Axonics Inc faces several fundamental risks that contribute to a negative outlook for its stock, including potential market share loss to competitors like Medtronic and challenges from new market entrants, which could hinder future growth prospects. The company's revenue growth has slowed to 32.3% in the third quarter of 2023, a decline from the previous quarter's 34.7%, indicating a troubling trend in sales momentum amidst increasing competition. Additionally, projections for revenue growth in a bear case scenario suggest that it could decline to between 15-20% or less due to slower market expansion and market share losses, raising concerns about the company's long-term financial performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.